Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALIENT: Vorasidenib + Lomustine in Recurrent IDH-mutant Glioma
NCT07629089Phase 1Not yet recruiting
- Sponsor
- Megan Mantica
- Start
- Nov 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorasidenib in IDH-mutant glioma, sponsored by Megan Mantica. Primary endpoint: Recommended Combination Dose at 42 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
vorasidenib
03
Conditions
IDH-mutant glioma
Beyond the preview
Go deeper on NCT07629089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629089.